{
  "id": 7680544,
  "title": "GSK licenses Chinese firm’s cancer drug in US$750 million deal",
  "url": "https://urgent.news/2026/09/16/gsk-licenses-chinese-firms-cancer-drug-in-us-750-million-deal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-16T02:00:05.000Z",
  "source": {
    "name": "SCMP Business",
    "slug": "scmp-business",
    "url": "https://www.scmp.com/business/china-business/article/3367631/gsk-licenses-chinese-firms-cancer-drug-us750-million-deal"
  },
  "original_language": "en",
  "account": "British pharmaceutical company GSK has reached a landmark agreement to acquire the rights to a groundbreaking cancer drug from Chinese biotechnology firm Chimagen Biosciences, in a deal valued at up to US$750 million. The acquisition underscores China's rising prominence in the biotech industry. GSK plans to secure full global rights to a T-cell engager (TCE) from Chengdu-based Chimagen, a drug targeting multiple myeloma, a form of blood cancer. TCEs function by directly binding to T cells, a type of white blood cell, and signaling the immune system to target cancer cells. Although existing TCEs effectively treat multiple myeloma, they frequently lead to severe side effects. Chimagen's new drug demonstrates potential for reduced side effects and more long-lasting results, according to GSK. GSK will make an upfront payment to Chimagen for the development and commercialization of its TCE assets, followed by further payments contingent on the drug's successful development and sales. The program is scheduled to commence phase one trials the following year. This deal highlights China's rapid advancement in biotechnology, which has attracted significant interest from global pharmaceutical companies and investors in recent years. In 2023 alone, out-licensing deals involving innovative Chinese drugs reached a total value of US$120 billion, marking a 36 per cent increase compared to the same period in 2022, according to data from China's National Medical Products Administration.",
  "summary": "British pharmaceutical giant GSK has agreed to acquire a cancer drug from Chinese firm Chimagen Biosciences in a deal worth up to US$750 million, underscoring China’s emergence as a global player in biotechnology. GSK announced plans on Tuesday to buy full global rights to a “potential best-in-class” T-cell engager (TCE) from Chengdu-based Chimagen, targeting treatment for multiple myeloma, a…",
  "key_points": [
    "GSK acquires rights to Chinese cancer drug in $750M deal",
    "T-cell engager targets multiple myeloma, a blood cancer",
    "Upfront payment and milestone payments tied to drug development"
  ],
  "editors_take": "This deal cements China's growing influence in the biotech sector, particularly as a source of innovative drugs that global pharmaceutical companies are eager to license and commercialize.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "South China Morning Post",
        "title": "GSK licenses Chinese firm’s cancer drug in US$750 million deal",
        "url": "https://urgent.news/2026/09/16/gsk-licenses-chinese-firms-cancer-drug-in-us-750-million-deal-7681291",
        "published": "2026-09-16T02:00:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}